近日,歌礼制药发布自愿性公告。披露公司近日获悉由石药集团有限公司附属公司康久普乐生物医疗有限公司向美国专利商标局(“USPTO”)提交的一项复审。该复审质疑本公司附属公司歌礼制药(中国)有限公司一项已获授权的美国专利的有效性。截至本公告日期,该复审仍在USPTO审查中。石药尚在专利申请中的化合物10(Compound 10,申请号:PCT/CN2024/140920;申请人:石药集团百克(山东)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.